James M. McKenney, PharmD

Articles by James M. McKenney, PharmD

Understanding Practice Patterns and Low-density Lipoprotein Cholesterol Goal Attainment Implications of Switching Patients From Simvastatin in a Health Plan Setting

ByCaroline R. Harley, PhD,Sanjay K. Gandhi, PhD,Nze Anoka, MS, MBA,Michael F. Bullano, PharmD,James M. McKenney, PharmD

December 1st 2007

Effectiveness and Cost-effectiveness of Rosuvastatin, Atorvastatin, and Simvastatin Among High-Risk Patients in Usual Clinical Practice

ByRobert L. Ohsfeldt, PhD,Sanjay K. Gandhi, PhD,Kathleen M. Fox, PhD, MPH,Thomas a. Stacy, PharmD,James M. McKenney, PharmD

November 1st 2006

An Assessment of Statin Safety

ByJames M. McKenney, PharmD

October 1st 2006

Statin Pharmacology May Have Important Clinical Implications

ByJames M. McKenney, PharmD

July 1st 2002

Lipid Management: Tools for Getting to the Goal

ByJames M. McKenney, PharmD

August 1st 2001

Introduction: Missing the Target with Lipid-Lowering Therapy

ByDonald B. Hunninghake, MD,James M. McKenney, PharmD

November 1st 2000

Improving Cholesterol Control in Managed Care Populations

ByJames M. McKenney, PharmD

November 1st 2000

Issues and Controversies in Pharmacoeconomics

ByWilliam F. McGhan, PharmD, PhD,James M. McKenney, PharmD,Susan Andrade, ScD,Sidney C. Smith, Jr, MD,Bruce Kinosian, MD,Joel W. Hay, PhD

April 1st 1998

Economic Benefits of Aggressive Lipid Lowering: A Managed Care Perspective

ByJames M. McKenney, PharmD,Bruce Kinosian, MD

January 1st 1998

Introduction: Creating an Optimal Strategy for Lipid Management

ByJames M. McKenney, PharmD,William H. Frishman, MD

December 1st 1996

Latest Updated Articles

Introduction: Missing the Target with Lipid-Lowering Therapy
November 1st 2000
Improving Cholesterol Control in Managed Care Populations
November 1st 2000
Statin Pharmacology May Have Important Clinical Implications
July 1st 2002
Economic Benefits of Aggressive Lipid Lowering: A Managed Care Perspective
January 1st 1998
Introduction: Creating an Optimal Strategy for Lipid Management
December 1st 1996
Understanding Practice Patterns and Low-density Lipoprotein Cholesterol Goal Attainment Implications of Switching Patients From Simvastatin in a Health Plan Setting
December 1st 2007

James M. McKenney, PharmD

Articles by James M. McKenney, PharmD

Understanding Practice Patterns and Low-density Lipoprotein Cholesterol Goal Attainment Implications of Switching Patients From Simvastatin in a Health Plan Setting

Effectiveness and Cost-effectiveness of Rosuvastatin, Atorvastatin, and Simvastatin Among High-Risk Patients in Usual Clinical Practice

An Assessment of Statin Safety

Statin Pharmacology May Have Important Clinical Implications

Lipid Management: Tools for Getting to the Goal

Introduction: Missing the Target with Lipid-Lowering Therapy

Improving Cholesterol Control in Managed Care Populations

Issues and Controversies in Pharmacoeconomics

Economic Benefits of Aggressive Lipid Lowering: A Managed Care Perspective

Introduction: Creating an Optimal Strategy for Lipid Management

Latest Updated Articles

Trending on AJMC

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

FDA Panel Backs 6 Peptides for Compounding

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

Boston Panel Confronts Access and Coordination Gaps in Obesity Care

Pediatric Chronic Skin Disorders Linked to Poorer Mental Health

A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact

James M. McKenney, PharmD

Articles by James M. McKenney, PharmD

Understanding Practice Patterns and Low-density Lipoprotein Cholesterol Goal Attainment Implications of Switching Patients From Simvastatin in a Health Plan Setting

Effectiveness and Cost-effectiveness of Rosuvastatin, Atorvastatin, and Simvastatin Among High-Risk Patients in Usual Clinical Practice

An Assessment of Statin Safety

Statin Pharmacology May Have Important Clinical Implications

Lipid Management: Tools for Getting to the Goal

Introduction: Missing the Target with Lipid-Lowering Therapy

Improving Cholesterol Control in Managed Care Populations

Issues and Controversies in Pharmacoeconomics

Economic Benefits of Aggressive Lipid Lowering: A Managed Care Perspective

Introduction: Creating an Optimal Strategy for Lipid Management

Latest Updated Articles

Trending on AJMC

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

FDA Panel Backs 6 Peptides for Compounding

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

Boston Panel Confronts Access and Coordination Gaps in Obesity Care

Pediatric Chronic Skin Disorders Linked to Poorer Mental Health